In anticipation of the potential commercialization of its Arikayce inhaled liposomal amikacin, Insmed has announced a number of management changes designed to “better align the organization with the company’s growth opportunities.”
Those changes are:
- Renu Gupta, currently Executive VP of Development and Chief Medical Officer, will become Special Advisor to the CEO until Fall 2014, when she will leave the company. Insmed has not yet named a replacement.
- Wes Kaupinen, VP of Corporate Development and Commercialization, will now report directly to the CEO.
- John Goll, formerly of Warner Chilcott, has been hired as VP, Corporate Controller.
- Drayton Wise, who headed up the US sales launch of TOBI Podhaler for Novartis, has joined Insmed as Senior Director of Commercial Operations.
- Jill Dolgin, most recently of Onyx Pharmaceuticals, has been hired as Senior Director of Patient Advocacy and Public Policy.
- Former Aptalis Pharmaceuticals Managed Markets director Kevin McDermott has been hired as Head of Global Market Access.
- Kevin Schutz, most recently of Antares Pharma, will be Senior Director of Regulatory Affairs.
Insmed President and CEO Will Lewis commented, “Over the past year, we have been evolving Insmed from a primarily R&D oriented company toward one capable of delivering and supporting multiple products in our targeted therapeutic areas — orphan, pulmonary and infectious diseases. The changes we are announcing today broaden the depth of talent and experience in all areas of our business — from R&D, regulatory and commercial to financial and corporate development — to ensure we deliver on our mission to provide new life-saving therapies to patients around the world.”
Read the Insmed press release.
